Novo Nordisk shares fall after Trump deal to slash obesity drug prices

Novo Nordisk's shares have taken a hit following President Trump's announcement to reduce prices on obesity medications. This move is significant as it could impact the company's revenue and market position, raising concerns among investors about the future profitability of its popular weight-loss drugs.